Northwestern University.
University of Newcastle.
Oncol Nurs Forum. 2021 Jan 4;48(1):112-120. doi: 10.1188/21.ONF.112-120.
To determine whether health-related quality of life (HRQOL) among individuals with cancer is undermined by smoking cessation treatment involving varenicline.
SAMPLE & SETTING: Participants (N = 103) were daily smokers with cancer (up to five years postdiagnosis) who completed a placebo-controlled trial of standard versus extended duration varenicline.
METHODS & VARIABLES: For this secondary study, participants were selected based on having completed the SF-12® at weeks 0, 1, 12, and 24. Using separate repeated measures multivariate analysis of variance, change in SF-12 scores was evaluated by time and by cancer treatment, varenicline duration, and quit status at week 24.
There was no change in any of the three HRQOL scores by time or by cancer treatment status, varenicline duration, or quit status. Average emotional HRQOL score across time was significantly higher for quitters versus smokers.
Varenicline, including long-term treatment, does not appear to adversely affect HRQOL, which is highly relevant to oncology nurses who are well positioned to assist with the pharmacologic treatment of tobacco dependence.
确定使用伐伦克林进行戒烟治疗是否会降低癌症患者的健康相关生活质量（HRQOL）。
参与者（N=103）为患有癌症（诊断后长达五年）的每日吸烟者，他们完成了一项关于标准疗程与延长疗程伐伦克林的安慰剂对照试验。
对于这项二次研究，根据参与者在第 0、1、12 和 24 周完成 SF-12®的情况选择参与者。使用单独的重复测量多元方差分析，通过时间以及癌症治疗、伐伦克林疗程和第 24 周的戒烟状态评估 SF-12 评分的变化。
在任何时间或癌症治疗状态、伐伦克林疗程或第 24 周的戒烟状态方面，三种 HRQOL 评分均无变化。戒烟者的平均情绪 HRQOL 评分在整个时间内均显著高于吸烟者。
伐伦克林，包括长期治疗，似乎不会对 HRQOL 产生不利影响，这对肿瘤护士具有重要意义，他们非常适合协助进行烟草依赖的药物治疗。
